Tharimmune Inc. (NASDAQ: THAR)
$4.03
-0.0450 ( -1.11% ) 4.2K
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
Market Data
Open
$4.03
Previous close
$4.07
Volume
4.2K
Market cap
$3.24M
Day range
$3.97 - $4.30
52 week range
$2.75 - $142.50
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 17 | Jun 20, 2024 |
8-k | 8K-related | 13 | Jun 11, 2024 |
8-k | 8K-related | 17 | Jun 07, 2024 |
8-k | 8K-related | 15 | May 22, 2024 |
8-k | 8K-related | 13 | May 14, 2024 |
10-q | Quarterly Reports | 43 | May 09, 2024 |
ars | Annual reports | 1 | Mar 22, 2024 |
def | Proxies and info statements | 4 | Mar 21, 2024 |
8-k | 8K-related | 15 | Mar 11, 2024 |
pre | Proxies and info statements | 4 | Mar 11, 2024 |